[1]袁作为,王永红,黄俊,等.HIV-1疫苗诱导与自然感染产生抗体鉴别诊断试纸研制及评价[J].第三军医大学学报,2019,41(07):678-683.
 YUAN Zuowei,WANG Yonghong,HUANG Jun,et al.Development and evaluation of a differential diagnostic test strip for antibodies induced by HIV-1 vaccine and natural infections[J].J Third Mil Med Univ,2019,41(07):678-683.
点击复制

HIV-1疫苗诱导与自然感染产生抗体鉴别诊断试纸研制及评价(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
41卷
期数:
2019年第07期
页码:
678-683
栏目:
基础医学
出版日期:
2019-04-15

文章信息/Info

Title:
Development and evaluation of a differential diagnostic test strip for antibodies induced by HIV-1 vaccine and natural infections
作者:
袁作为王永红黄俊叶杨敏
重庆市黔江中心医院:检验科,输血科
Author(s):
YUAN Zuowei WANG Yonghong HUANG Jun1 YE Yangmin

Department of Laboratory Medicine, Department of Blood Transfusion, Qianjiang Central Hospital, Chongqing, 409099, China

关键词:
HIV-1自然感染疫苗抗体鉴别诊断诊断试剂盒  
Keywords:
HIV-1 natural infection vaccine antibody differential diagnosis diagnostic reagent kits
分类号:
R446.11; R447; R512.91
文献标志码:
A
摘要:

目的 研制区分HIV-1自然感染与HIV-1疫苗诱导产生抗体的鉴别诊断试纸条,并对其诊断性能进行评价。方法 将前期利用原核表达获取的HIV-1包膜蛋白gp41和鉴别融合肽段SK1-SK2-SK3分别包被NC膜,结合胶体金标记抗人蛋白A,研制新型HIV-1抗体鉴别诊断试纸条;采用新型试纸条检测评价HIV-1阳性血清、HIV阴性血清、HIV血清盘、HIV天坛疫苗血清及其他交叉反应血清,并与ELISA结果进行对比。结果 成功研制了HIV-1疫苗诱导与自然感染产生抗体的鉴别诊断试纸条,SK1-SK2-SK3检测灵敏度为93.5%,检测特异性为100.0%,联合gp41后的HIV1检出灵敏度可达100.0%;试纸条检测结果与ELISA检测结果一致(P>0.05);采用该试纸条检测天坛疫苗血清,SK1-SK2-SK3检测带均为阴性,避免了gp41条带检出的假阳性结果。结论 该新型HIV-1抗体诊断试纸条能够有效区分HIV-1自然感染与HIV-1疫苗接种后产生的抗体,避免目前市售试剂盒的假阳性诊断。

Abstract:

Objective To develop a differential diagnostic kit for distinguishing antibodies induced by HIV-1 infection and HIV-1 vaccine and evaluate its diagnostic performance. Methods Nitrocellulose membrane was coated with HIV-1 envelope protein gp41 and HIV-1 recognition fusion peptide SK1-SK2-SK3 obtained using a prokaryotic expression system. The differential diagnostic test strip for HIV-1 antibodies was prepared by assembling the coated membrane with a non-woven fabric coated with protein A-coupled colloidal gold. The performance of the test strip was evaluated using samples of HIV-positive sera, HIV-negative sera, HIV serum panel, HIV Tiantan vaccine sera and other cross-reactive sera, and the test results using this strip were compared with those by ELISA. Results The sensitivity of SK1-SK2-SK3 coating on the novel differential diagnostic test strip for HIV-1 antibody detection was 93.5% , with a detection specificity of 100.0%. When combined with gp41 coating, the test strip showed a diagnostic sensitivity of 100.0%. The test results with the strip were consistent with those by ELISA (P>0.05). For the Tiantan vaccine serum, the SK1-SK2-SK3 coating on the strip all yielded negative results without the false positive results of the gp41 coating. Conclusion This novel HIV-1 antibody diagnostic test strip can effectively distinguish the antibodies produced by HIV-1 infection from those generated by HIV-1 vaccination without false positive results as are common with the currently available commercial HIV test kits.

参考文献/References:

[1]VORONIN Y, ZINSZNER H, KARG C, et al. HIV vaccineinduced seroreactivity: a challenge for trial participants, researchers, and physicians[J]. Vaccine, 2015, 33(10): 1243-1249. DOI: 10.1016/j.vaccine.2014.10.040.
[2]ACKERMAN M E, BAROUCH D H, ALTER G. Systems serology for evaluation of HIV vaccine trials[J]. Immunol Rev, 2017, 275(1): 262-270. DOI: 10.1111/imr.12503.
[3]KHURANA S, NORRIS P J, BUSCH M P, et al. HIV-selectest enzyme immunoassay and rapid test: ability to detect seroconversion following HIV1 infection[J]. J Clin Microbiol, 2010, 48(1): 281-285. DOI: 10.1128/JCM.01573-09.
[4]KHURANA S, NEEDHAM J, PARK S, et al. Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV1 subtypes[J]. J Acquir Immune Defic Syndr, 2006, 43(3): 304-312. DOI: 10.1097/01.qai.000024 2465.50947.5f.
[5]KHURANA S, NEEDHAM J, MATHIESON B, et al. Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccinegenerated antibodies[J]. J Virol, 2006, 80(5): 2092-2099. DOI: 10.1128/JVI.80.5.2092-2099.2006.
[6]袁作为, 帅光泽, 张君, 等. HIV跨膜蛋白gp41和gp36原核表达及抗原性研究[J]. 第三军医大学学报, 2010, 32(21): 2281-2285.
YUAN Z W, SHUAI G Z, ZHANG J, et al. Expression of HIV transmembrane protein gp41 and pronucleus gp36 and their antigenicity[J]. J Third Mil Med Univ, 2010, 32(21): 2281-2285.
[7]YUAN Z W, CHEN W X, ZHANG J, et al. Development of an immunoassay for differentiating human immunodeficiency virus infections: from vaccine-induced immune response in Tiantan vaccine trials in China[J]. Clin Biochem, 2012, 45(15): 1219-1224.
[8]袁作为, 张君, 胡接力, 等. HIV自然感染与疫苗诱导产生抗体鉴别肽的原核表达及纯化[J].中国生物制品学杂志, 2011, 24(11):1254-1258, 1263. DOI:10.13200/j.cjb.2011.11.11.yuanzw.019.
YUAN Z W, ZHANG J, HU J L, et al. Prokaryotic expression and purification of HIV differential peptides for natural infection-elicited and vaccine-induced antibodies [J]. Chin J Biologicals, 2011,24(11):1254-1258, 1263. DOI: 10.13200/j.cjb.2011.11.11.yuanzw.019.
[9]GINN S L, AMAYA A K, ALEXANDER I E, et al. Gene therapy clinical trials worldwide to 2017: An update[J]. J Gene Med, 2018, 20(5): e3015. DOI: 10.1002/jgm.3015.
[10]ACKERS M L, PAREKH B, EVANS T G, et al. Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients[J]. J Infect Dis, 2003, 187(6): 879-886. DOI: 10.1086/368169.
[11]PITISUTTITHUM P, NITAYAPHAN S, THONGCHAROEN P, et al. Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults[J]. J Infect Dis, 2003, 188(2): 219-227. DOI: 10.1086/376506.
[12]ALLEN M, ISRAEL H, RYBCZYK K, et al. Trial-related discrimination in HIV vaccine clinical trials[J]. AIDS Res Hum Retroviruses, 2001, 17(8): 667-674. DOI: 10.1089/088922201750236942.
[13]ANDRABI R, BHIMAN J N, BURTON D R. Strategies for a multi-stage neutralizing antibody-based HIV vaccine[J]. Curr Opin Immunol, 2018, 53: 143-151. DOI: 10.1016/j.coi.2018.04.025.
[14]KONG R, XU K, ZHOU T Q, et al. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody[J]. Science, 2016, 352(6287): 828-833. DOI: 10.1126/science.aae0474.
[15]LIAO H X, LYNCH R, ZHOU T Q, et al. Coevolution of a broadly neutralizing HIV-1 antibody and founder virus[J]. Nature, 2013, 496(7446): 469-476. DOI: 10.1038/nature12053.
[16]DAVID D,GOOSSENS D,DESGRANGES C,et al. Molecular characterization of human monoclonal antibodies specific for several HIV proteins: analysis of the VH3 family expression [J].Immunol Lett,1995, 47(1/2):107-112.
[17]ACKERS M L, PAREKH B, EVANS T G, et al. Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients[J]. J Infect Dis, 2003, 187(6): 879-886. DOI: 10.1086/368169.
[18]ZHANG Q C, LIU Z, HOU J, et al. Improved safety of a replication-competent poxvirus-based HIV vaccine with the introduction of the HSV-TK/GCV suicide gene system[J]. Vaccine, 2016, 34(30): 3447-3453. DOI: 10.1016/j.vaccine.2016.05.012.
[19]ZHANG Q C, TIAN M J, FENG Y, et al. Genomic sequence and virulence of clonal isolates of vaccinia virus Tiantan, the Chinese smallpox vaccine strain[J]. PLoS ONE, 2013, 8(4): e60557. DOI: 10.1371/journal.pone.0060557.
 

更新日期/Last Update: 2019-04-05